NR1H4 and Hyperbilirubinemia: In a 2021, research paper van der Schoor and co-workers investigated instead the potential of therapeutic bile acids UDCA and obeticholic acid (OCA, 6-α-ethyl-CDCA), a farnesoid-X-receptor (FXR) agonist (Figure 8), as preventive treatment options for neonatal hyperbilirubinaemia.97